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Background—Obstructive sleep apnea (OSA) is associated with recurrent atrial fibrillation (AF) after electrocardioversion.
OSA is highly prevalent in patients who are male, obese, and/or hypertensive, but its prevalence in patients with AF is
unknown.
Methods and Results—We prospectively studied consecutive patients undergoing electrocardioversion for AF (n151)
and consecutive patients without past or current AF referred to a general cardiology practice (n312). OSA was
diagnosed with the Berlin questionnaire, which is validated to identify patients with OSA. We also assessed its accuracy
compared with polysomnography in a sample of the study population. Groups were compared with the 2-tailed t,
Wilcoxon, and 2 tests. Logistic regression modeled the association of AF and OSA after adjustment for relevant
covariates. Patients in each group had similar age, gender, body mass index, and rates of diabetes, hypertension, and
congestive heart failure. The questionnaire performed with 0.86 sensitivity, 0.89 specificity, and 0.97 positive predictive
value in our sample. The proportion of patients with OSA was significantly higher in the AF group than in the general
cardiology group (49% versus 32%, P0.0004). The adjusted odds ratio for the association between AF and OSA was
2.19 (95% CI 1.40 to 3.42, P0.0006).
Conclusions—The novel finding of this study is that a strong association exists between OSA and AF, such that OSA is
strikingly more prevalent in patients with AF than in high-risk patients with multiple other cardiovascular diseases. The
coinciding epidemics of obesity and AF underscore the clinical importance of these results. (Circulation. 2004;110:364-
367.)
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Atrial fibrillation (AF) is a growing public health concernand has been described as an emerging epidemic.1 The
age-adjusted prevalence of AF in the United States has tripled
from the 1960s to late 1980s.2 In the year 2000, approxi-
mately 2 million American adults had AF,3 and this number
is expected to exceed 5 million by 2050.4 This trend is a cause
for alarm given the significant morbidity, mortality, and
economic costs associated with AF.5,6
Obesity, too, is recognized as a national and worldwide
epidemic.7,8 The prevalence of obstructive sleep apnea (OSA) is
directly related to body mass index, and more than 40% of obese
patients have OSA.9 The parallel epidemiological phenomena of
AF and obesity might reflect common risk factors or, alterna-
tively, a physiological interaction of these conditions. OSA and
AF share many risk factors and comorbidities, including male
gender, hypertension, congestive heart failure, and coronary
artery disease.10 Studies in patients with congestive heart failure
noted an increased prevalence of AF in those patients with sleep
apnea.11,12 The presence of sleep apnea was shown to predict
predischarge AF after coronary bypass surgery.13 Furthermore,
untreated OSA doubles the risk of recurrence of AF in patients
after electrical cardioversion, and treatment of OSA with con-
tinuous positive airway pressure attenuates that risk.14
Although OSA and AF share numerous disease associa-
tions, the prevalence of OSA in patients with AF is unknown.
Because OSA is significantly underdiagnosed,15 and treat-
ment of OSA lowers the risk of recurrent AF,14 determining
the prevalence of OSA in patients with AF is clinically
important. We tested the hypothesis that the prevalence of
OSA in patients with AF is higher than that in nonselected
cardiology practice patients with risk factors for OSA but no
past or current AF.
Methods
Study Population
We prospectively assessed the risk of OSA in 524 patients. The AF
group included 151 consecutive patients with AF or flutter referred
to the Mayo Clinic Cardioversion Center for electrical cardioversion.
The general cardiology group included 373 consecutive patients who
were referred to a general cardiology practice for cardiovascular
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disease management. Sixty-one patients with past or current AF were
excluded from the latter group. Characteristics of the study popula-
tion are described in Table 1.
Diagnosis of OSA
The presence of OSA was determined by the Berlin questionnaire, a
validated instrument designed to identify individuals with OSA.16,17
The questionnaire includes 1 introductory and 4 follow-up questions
about snoring, 3 questions about daytime somnolence (including 1
concerning sleepiness while driving), and 1 question about history of
hypertension. It also collects information about age, gender, race and
ethnicity, height, weight, and neck circumference. Presence of OSA
is determined by positive responses to at least 2 of the following 3
criteria: (1) persistent symptoms (3 times per week) for at least 2
snoring questions, (2) persistent (3 times per week) somnolence
during daytime and/or while driving, and (3) history of hypertension
or a body mass index30 kg/m2. The questionnaire has high internal
validity (Cronbach correlations 0.86 to 0.92) and performs accu-
rately, with a sensitivity of 0.86, specificity of 0.77, and a positive
predictive value of 0.89 in a primary care setting.17
Validation of the Questionnaire
We validated the accuracy of the questionnaire in our study popu-
lation by assessing its results in patients who had undergone formal
sleep studies (n 44), which were performed by monitoring of the
electroencephalogram, electrooculogram, submental and anterior
tibial electromyograms, ECG, thoracoabdominal excursions (by
respiratory inductive plethysmography), oronasal airflow (by ther-
mistor or airflow pressure transducer), and arterial oxygen saturation
(by pulse oximetry). An apnea was defined as a cessation of airflow
for 10 seconds and hypopnea as a 50% reduction in airflow for
10 seconds, both in the setting of active ventilatory efforts. The
apnea-hypopnea index was calculated as the mean number of apneas
and hypopneas per hour of sleep. The diagnosis of OSA was
established in accordance with the sleep study criteria recommended
by the American Academy of Sleep Medicine.18 The sensitivity,
specificity, and positive predictive value of the questionnaire in our
study sample was calculated using the sleep study results as the “gold
standard.”
Patients with OSA identified by the questionnaire received a letter
that described the finding and recommended consultation with their
personal physician. Informed consent was obtained from all partic-
ipants, and the institutional committees on human research approved
the study.
Statistical Analysis
Characteristics of the study population were expressed as means
(with SDs), medians (with interquartile ranges), and counts (with
percentages). Differences between the AF group and the general
cardiology group were tested by the unpaired t test or Wilcoxon
rank-sum test for continuous variables and the 2 test for categorical
variables. We calculated Bayesian confidence intervals (CI) for the
proportions of patients with OSA in the AF group and the general
cardiology group, and the proportions were compared by the 2 test.
Statistical significance was established by 0.05. The OR and 95%
CI for the association between OSA and covariates were assessed by
univariate logistic regression. After adjustment for relevant covari-
ates, multiple logistic regression modeled the adjusted OR and 95%
CI for the association between AF and OSA.
Results
Characteristics of Study Population
Table 1 describes the characteristics of the study population.
The AF Group and General Cardiology Group had statisti-
cally similar gender distribution, age, body mass index, and
rates of diabetes, hypertension, and congestive heart failure.
The AF Group had slightly larger neck circumference (41
versus 40 cm, P0.001) and a significantly lower rate of
coronary artery disease (33% versus 50%, P0.001).
Validation of Questionnaire
Compared with the gold standard of an overnight sleep study,
the questionnaire performed with 0.86 sensitivity and 0.89
specificity and had a positive predictive value of 0.97 for
OSA. The mean apnea-hypopnea index was 56 (34) in
patients whom the questionnaire identified as having OSA,
compared with 1.4 (1.3) in patients whom it identified as
not having OSA (P0.0001).
Association of AF and OSA
The proportion of patients with OSA was significantly higher
in the AF group than in the general cardiology group (49%
[95% CI 41% to 57%] versus 32% [95% CI 27% to 37%],
P0.0004; Figure 1). Furthermore, to take into account
potential misclassifications of OSA diagnoses by the ques-
tionnaire, we also analyzed a worst-case scenario in which the
TABLE 1. Characteristics of the Study Population
AF
Patients
(n151)
General Cardiology
Patients
(n312) P
Male gender, n (%) 97 (64) 181 (58) 0.200
White race, n (%) 148 (98) 289 (93) 0.018
Age, y
MeanSD 7112 6814 0.078
Median, IQR 73 (66–78) 71 (60–78)
Body mass index, kg/m2
MeanSD 296 296 0.617
Median, IQR 28 (24–32) 28 (25–33)
Neck circumference, cm
MeanSD 415 405 0.001
Median, IQR 41 (38–44) 39 (36–42)
Hypertension, n (%) 99 (66) 215 (69) 0.441
Diabetes, n (%) 26 (17) 74 (24) 0.107
Coronary artery disease, n (%) 49 (33) 157 (50) 0.001
Congestive heart failure, n (%) 28 (19) 38 (12) 0.068
IQR indicates interquartile range.
Figure 1. Proportion and 95% CI of patients with OSA. Preva-
lence of OSA is significantly higher in patients with AF than in
patients without past or current AF in general cardiology prac-
tice (49% [95% CI 41% to 57%] vs 32% [95% CI 27% to 37%],
P0.0004).
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difference between groups was minimized by decreasing the
number of OSA patients in the AF group by the false-positive
rate (0.032) and increasing the number of OSA patients in the
general cardiology group by the false-negative rate (0.143).
Even then, the proportion of patients with OSA in the AF
group was significantly higher than that in the general
cardiology group (48% versus 37%, P0.022). Univariate
analysis identified significant associations between OSA and
body mass index, neck circumference, hypertension, diabetes
mellitus, and AF (OR 1.89, 95% CI 1.28 to 2.83, P0.002;
Table 2). In multivariate analysis, body mass index, hyper-
tension, and AF remained significantly associated with OSA,
and the OR was largest for AF (2.19, 95% CI 1.40 to 3.42,
P0.0006; Figure 2).
Discussion
The novel findings of the present study are that approxi-
mately half of patients with AF are likely to have OSA and
that the association of OSA with AF was greater than the
association of OSA with traditional OSA risk factors such as
body mass index, neck circumference, and hypertension. The
study also confirmed that established cardiovascular diseases,
such as coronary artery disease and congestive heart failure,
are accompanied by a high prevalence of OSA.19,20 Further-
more, the prevalence of OSA in patients with AF was
substantially greater than the prevalence of OSA in patients
with established cardiovascular disease but without past or
current AF.
These findings support the concept that it is not only the
associated conditions of OSA (most importantly hyperten-
sion) that may lead to AF, but there may be a unique
interaction between the pathophysiologies of OSA and AF. In
patients with OSA, intermittent hypoxemia, hypercapnia,
chemoreceptor excitation, markedly increased sympathetic
drive, and severe pressor surges,21 all of which occur nightly
for years if untreated, may initiate or predispose to AF.
Hypoxemia and hypercapnia themselves are arrhythmo-
genic.22,23 Nocturnal increases in sympathetic activation per-
sist during wakefulness in patients with OSA,24 and increased
sympathetic drive is associated with AF.25,26 The forceful
ventilatory efforts against upper airway obstruction during
apneas result in dramatic shifts in transmural pressures and
measurable changes in cardiac chamber dimensions.27,28
These acute structural changes may promote AF via the
triggering of stretch-activated atrial ion channels.29 In addi-
tion, severity of OSA is independently associated with
elevated markers of systemic inflammation, including
C-reactive protein.30 C-reactive protein, in turn, is directly
associated with an increasing burden of AF.31
Although these mechanisms are likely to explain the
relationship between OSA and AF, the reverse paradigm may
be true in some patients in whom atrial arrhythmias play a
role in causing OSA. This concept is relevant to the finding
that atrial overdrive pacing reduced the severity of sleep
apnea in a small group of patients with sinus node dysfunc-
tion.32 The pathophysiology is unclear but may relate to
effects of atrial arrhythmias on cardiac afferent autonomic
activity and central nervous system mechanisms that direct
ventilatory control and airway muscle activity.33,34
The use of the Berlin questionnaire to identify patients with
OSA may be seen as a limitation of the study, because
overnight sleep studies are the gold standard for the diagnosis
of OSA. However, in addition to the questionnaire’s estab-
lished validity in a primary care setting,17 we confirmed that
it was extremely accurate in the present study population. We
showed in a subgroup of our study population that the
questionnaire predicted 86% of cases and that 97% of those
predicted indeed had OSA by complete overnight sleep
studies. The performance of the questionnaire was slightly
better than in previous studies,16,17 likely due to the higher
prevalence of OSA in the present study sample. Even in a
hypothetical worst-case scenario, in which we maximized
potential misdiagnoses of OSA to minimize the difference in
OSA prevalence between the groups, the proportions of
patients with OSA in the AF group remained significantly
higher than that in the general cardiology group. Thus, the
questionnaire accurately and efficiently identified patients
with OSA in a large sample of patients with a spectrum of
cardiovascular diseases, and the general results of the study
would be unchanged even if the performance of the question-
naire was biased to show no difference between the groups.
There are important clinical implications of the present
study’s finding that a striking proportion of patients with AF
also have OSA, especially as the number of patients with
obesity and AF grows. Given recent data about the increased
recurrence of AF in patients with untreated OSA and the
lower risk of recurrence with continuous positive airway
TABLE 2. Unadjusted ORs and 95% CIs for OSA
OR 95% CI P
Male gender 1.09 0.90–1.32 0.378
Age, y 0.99 0.97–1.00 0.085
Body mass index, kg/m2 1.12 1.08–1.16 0.0001
Neck circumference, cm 1.11 1.06–1.15 0.0001
Hypertension 1.28 1.04–1.57 0.019
Diabetes mellitus 1.33 1.08–1.69 0.008
Coronary artery disease 1.03 0.85–1.24 0.754
Congestive heart failure 1.06 0.81–1.38 0.669
AF 1.89 1.28–2.82 0.002
Figure 2. Adjusted OR and 95% CI for association between AF
and OSA. After adjustment for body mass index, neck circum-
ference (neck circ), hypertension, and diabetes mellitus, AF is
significantly associated with OSA (OR 2.19, 95% CI 1.40 to
3.42, P0.0006).
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pressure therapy, it would be important to identify the large
proportion of patients with AF who have OSA and are
eligible for such treatment. The presence of OSA should be
considered in all patients with AF, and screening might be
warranted in patients with AF who are obese or hypertensive.
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